Feb 11 (Reuters) - Australia's CSL Ltd CSL.AX reported a 5% rise in its first-half profit on Tuesday, boosted by growth in its core immunoglobulin business across geographies.

The biotech giant said that its underlying net profit after tax attributable for the six months ended December 31 was $2.11 billion, on a constant currency basis, compared with $2.06 billion reported a year ago.

(Reporting by Aaditya Govind Rao and Shivangi Lahiri in Bengaluru; Editing by Alan Barona)

((Shivangi.Lahiri@thomsonreuters.com))